Apps

News

Brands

FDA Approves Kerendia, First Type 1 CKD Drug — 2dFDA approved Bayer's Kerendia on Sep 17, 2026 for type 1 diabetes CKD—the first new treatment in over 30 years—after FINE-ONE showed a 25% UACR cut versus placebo.

Dana Whitfield Bayer's focus on lowering albumin levels makes sense if it actually slows progression in real use.

Novo says Wegovy trial moved 40% of young children out of obesity — Sep 7, 2026In Novo Nordisk's STEP Young phase 3 trial, once-weekly semaglutide plus lifestyle changes reduced BMI and 40.4% of children aged 6-11 with obesity no longer met obesity criteria after 68 weeks, versus 0% on placebo. Safety remained consistent with prior semaglutide studies, adding to the growing body of pediatric obesity treatment data.

Chris Dalton Glad there's finally something beyond diet and exercise lectures for kids who genuinely struggle, this could change a lot of families' lives.

Novo Nordisk Tests Lower Wegovy Doses — Aug 19, 2026Novo Nordisk is conducting a late-stage study to identify the lowest effective dose of Wegovy, testing two low doses against placebo in 450 participants as it seeks to preserve its share in a obesity drug market projected to exceed $100 billion annually by 2030. The trial, which began on August 12 and runs through 2028, follows competitive pressure from Eli Lilly and comes after Wegovy's recent sales performance, with dose strengths undisclosed.